Beactica and KU Leuven secure EUR 2.5 million from the European Innovation Council to advance orphan drug BEA-17 to clinical readiness

(LISCO), where Prof. Voet contributes leading expertise in advanced (spatial) single-cell technologies. As part of the KU Leuven Cancer Institute, these molecular insights are functionally tested by Prof. Coosemans' team using state-of-the-art GBM mouse models and drug profiling platforms, providing a critical translational step toward the clinic. By integrating patient data, single-cell technologies and preclinical validation, this collaboration establishes a focused pipeline aimed at enabling the next generation of clinical testing for GBM at KU Leuven.

Beactica Therapeutics contact
Per Källblad M.Sc. Ph.D.
CEO
per.kallblad@beactica.com 
Tel: +46 18 56 08 80

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/beactica-therapeutics-ab/r/beactica-and-ku-leuven-secure-eur-2-5-million-from-the-european-innovation-council-to-advance-orphan,c4308175

The following files are available for download:

https://mb.cision.com/Main/17268/4308175/3936302.pdf

Press release (PDF)

 

View original content:https://www.prnewswire.co.uk/news-releases/beactica-and-ku-leuven-secure-eur-2-5-million-from-the-european-innovation-council-to-advance-orphan-drug-bea-17-to-clinical-readiness-302689299.html

en | boerse | 68738428 |